BPG is committed to discovery and dissemination of knowledge
Articles in Press
11/17/2025 6:18:58 AM | Browse: 83 | Download: 16
Publication Name World Journal of Gastroenterology
Manuscript ID 113181
Country China
Category Gastroenterology & Hepatology
Manuscript Type Basic Study
Article Title Anwei decoction alleviates chronic atrophic gastritis by modulating the gut microbiota-metabolite axis and NLRP3 inflammasome activity
Manuscript Source Unsolicited Manuscript
All Author List Hong Qin, Yi-Yang Liu, Qiang Li, Sai-Yan Wei, Li-Yun Huang, Chai-Feng Zhou, Li-Yan Tan, Jing-Wen Zhang, De-Kun Wu and You-Ming Tang
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Science Foundation of China No. 81860843
Guangxi Administration of Traditional Chinese Medicine Project No. GZSY23-36
Guangxi Administration of Traditional Chinese Medicine Project No. GXZYA20240150
Corresponding Author De-Kun Wu, Associate Professor, Professor, Teaching Experiment and Training Center, Guangxi University of Chinese Medicine, No. 179 East Mingxiu Road, Xixiangtang District, Nanning 530000, Guangxi Zhuang Autonomous Region, China. 1278323777@qq.com
Key Words Anwei decoction; Chronic atrophic gastritis; Gut microbiota-metabolite axis; NLRP3 inflammasome; Traditional Chinese medicine
Core Tip Chronic atrophic gastritis (CAG) is a precancerous lesion of the stomach, with a prevalence of 34.7% in China and a risk of gastric cancer that is 4 times that of ordinary people. Existing therapies have high side effects and cannot reverse pathological damage. Traditional Chinese medicine Anwei decoction inhibits NLRP3 inflammasomes, reshapes the balance of microflora, breaks through the limitations of single targets, and provides a new strategy for CAG treatment, which can delay cancer and reverse pathological damage through the regulation of the “microbiota-metabolism-immunity” network.
Citation Qin H, Liu YY, Li Q, Wei SY, Huang LY, Zhou CF, Tan LY, Zhang JW, Wu DK, Tang YM. Anwei decoction alleviates chronic atrophic gastritis by modulating the gut microbiota-metabolite axis and NLRP3 inflammasome activity. World J Gastroenterol 2025; In press
Received
2025-08-25 06:05
Peer-Review Started
2025-08-25 06:06
To Make the First Decision
Return for Revision
2025-09-22 09:37
Revised
2025-10-03 17:34
Second Decision
2025-11-17 02:37
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief
2025-11-17 06:18
Articles in Press
2025-11-17 06:18
Publication Fee Transferred
2025-10-07 13:58
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com